As schizophrenia is genetically and clinically heterogeneous, systematic investigations are required to determine whether ICD-10 or DSM-IV categorical diagnoses identify a phenotype suitable and sufficient for genetic research, or whether correlated phenotypes incorporating neurocognitive performance and personality traits provide a phenotypic characterisation that accounts better for the underlying variation. We utilised a grade of membership (GoM) model (a mathematical typology developed for studies of complex biological systems) to integrate multiple cognitive and personality measurements into a limited number of composite graded traits (latent pure types) in a sample of 61 nuclear families comprising 80 subjects with ICD-10/ DSM-IV schizophrenia or schizophrenia spectrum disorders and 138 nonpsychotic firstdegree relatives. GoM probability scores, computed for all subjects, allowed individuals to be partly assigned to more than one pure type. Two distinct and contrasting neurocognitive phenotypes, one familial, associated with paranoid schizophrenia, and one sporadic, associated with nonparanoid schizophrenia, accounted for 74% of the affected subjects. Combining clinical diagnosis with GoM scores to stratify the entire sample into liability classes, and using variance component analysis (SOLAR), in addition to parametric and nonparametric multipoint linkage analysis, we explored candidate regions on chromosomes 6, 10 and 22. The results indicated suggestive linkage for the familial neurocognitive phenotype (multipoint MLS 2.6 under a low-penetrance model and MLS43.0 under a high-penetrance model) to a 14 cM area on chromosome 6, including the entire HLA region. Results for chromosomes 10 and 22 were negative. The findings suggest that the familial neurocognitive phenotype may be a pleiotropic expression of genes underlying the susceptibility to paranoid schizophrenia. We conclude that use of composite neurocognitive and personality trait measurements as correlated phenotypes supplementing clinical diagnosis can help stratify the liability to schizophrenia across all members of families prior to linkage, allow the search for susceptibility genes to focus selectively on subsets of families at high genetic risk, and augment considerably the power of genetic analysis.
Introduction
Schizophrenia affects approximately 1% of the population worldwide, presenting with similar clinical syndromes and comparable incidence rates across geographic regions. 1 It accounts for 2.3% of the global burden of disease 2 and shares many of the features of the common complex diseases. In the light of its high heritability, 3 there have been numerous attempts to identify the underlying genetic basis. In the last decade, data from at least 13 genome scans have been published, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] implicating regions on more than half of the chromosomes. 17 None of these findings have yet been consistently replicated, 18, 19 although some converging evidence is emerging of linkage on chromosomes 6p, 10p and 22q. However, the implicated regions are wide and there is considerable disagreement regarding the exact location of the putative genes. Association studies have been similarly inconclusive, notwithstanding some suggestive evidence implicating the serotonin 5HT 2a and the dopamine DRD 3 receptor genes. 20 Both linkage and association research strategies face a common problem in the identification of the relevant phenotype(s). The majority of genetic studies remain predicated on a clinical symptom-based phenotype, defined by the current diagnostic criteria of the disorder. However, finding individual susceptibility loci using diagnosis as a phenotype may be problematic. [21] [22] [23] Whereas schizophrenia is broadly heritable as a complex clinical entity, its symptoms show significant inter-and intra-individual variation, both cross-sectionally and over time, 24 and may not provide robust phenotypes for genetic study. Moreover, the genotypes underlying schizophrenia tend to remain clinically unexpressed in the majority (80-90%) of first-degree relatives. 25 The requirement for a phenotype which is stable and has a high relative risk ratio, 26 l R , can be addressed by augmenting the diagnostic description of schizophrenia with measurements of heritable biological traits that are plausibly implicated in pathogenesis and may be more directly influenced by genes coding for structural proteins or signalling molecules than clinical symptoms, such as delusions or hallucinations. Recent research has revealed a range of neurocognitive, neurophysiological and neuroanatomic abnormalities in nonpsychotic biological relatives of probands with schizophrenia, which possess many of the characteristics of vulnerability markers and are relatively specific to schizophrenia as compared to other psychotic disorders. [27] [28] [29] [30] Terms such as endophenotypes, correlated phenotypes, or level II indicators are used to describe this intermediate level. A genetic relationship between these phenotypes and schizophrenia is strongly suggested by studies on monozygotic twins discordant for the clinical disorder. 31, 32 The notion that using such correlated traits might dramatically enhance the capacity to detect linkage is supported by recent findings. Thus, Arolt et al 33 scanned the 6p21-23 region with 16 microsatellite markers to test for linkage to eye tracking dysfunction and schizophrenia. Two-point lod scores of 3.51 and 3.44 were found for markers D6S271 and D6S282 which, when included in a multipoint analysis, yielded a lod score of 4.02. Using both parametric and nonparametric (sib-pair) analysis of 104 members from nine families phenotyped for the auditory evoked potential P 50 (indexing a sensory gating defect in schizophrenia patients), Freedman et al 34 reported a multipoint lod score of 5.29 for a marker on chromosome 15q13-14, which falls within the region coding for the a7-nicotinic cholinergic receptor. A genome-wide linkage analysis, screening for loci underlying a composite inhibitory phenotype combining the P 50 event-related potential and antisaccade oculomotor performance measures, 35 produced evidence for linkage (lod score 3.55) to the D22S315 marker on chromosome 22q. Further promising endophenotypes for schizophrenia include reduced hippocampal volume 36 or neurocognitive deficits in attention control and executive function. 37 Faraone et al 38 estimated familial risk ratios for several phenotypes correlated with schizophrenia and concluded that among all the measures examined, an attentional deviance index, derived by Cornblatt et al 39 and based mainly on the identical pairs version of the Continuous Performance Task (CPT-IP), yielded the highest familial risk ratio of 30. Analysing differences in the profiles of neuropsychological deficits in twins discordant for schizophrenia, Cannon et al 32 suggested that at least partially distinct sets of genes for schizophrenia contribute to such variation, and concluded that measurement of neurocognitive profiles in patients and first-degree relatives may enable the determination of the segregation of specific deficits within families.
We report results from a family study in which we constructed a set of neurocognitive phenotypes correlated with schizophrenia by integrating measurements on multiple neurocognitive tasks and personality traits acquired from patients with schizophrenia and schizophrenia spectrum disorders, their biological first-degree relatives, and nonpsychiatric control subjects. We used grade of membership (GoM) analysis, a statistical technique based on a fuzzy sets mathematical model, 40, 41 to derive an empirical taxonomy of neurocognitive deficits and behavioural traits in schizophrenia that excluded clinical variables. External criteria, including clinical symptoms and other descriptors of illness, were later adduced to test the construct and predictive validity of the resultant taxonomy of neurocognitive deficit as putative endophenotypes. We describe firstly the results of variance component linkage analysis between markers in three candidate regions (chromosomes 6, 10 and 22) and the neurocognitive endophenotypes. Secondly, we report on parametric linkage analysis, carried out by combining the clinical phenotype with the neurocognitive endophenotypes. Thirdly, we present additional quantitative trait analyses for selected correlated phenotypes. To our knowledge, this is the first application of GoM to the genetic analysis of neurocognitive deficits in schizophrenia.
Materials and methods

Family ascertainment
Families were recruited by screening consecutive admissions to a major psychiatric hospital. Inclusion criteria were: (i) probands (age 15-54) met both ICD-10 and DSM-IV criteria for a lifetime diagnosis of schizophrenia or schizophrenia spectrum disorder; and (ii) at least one sibling and one parent were available for the study. Schizophrenia spectrum diagnoses included schizoaffective disorder, schizotypal and paranoid personality disorder, and other nonaffective psychoses (excluding persistent delusional disorders). Families were excluded if the proband had a comorbid organic brain disease or substance-use disorder that could account for the psychotic symptoms, or had language difficulties likely to interfere with interviewing or testing. The study protocol was explained to all participants and written informed consent was obtained. The Committee for Human Rights of the University of Western Australia and the Graylands Hospital Ethics Committee (Perth, Western Australia, Australia) approved the study.
Clinical evaluation
Probands and relatives were interviewed using the Schedule for Clinical Assessment in Neuropsychiatry, SCAN, Version 2.0. 42 Full pedigree description and history of psychiatric and general morbidity were obtained from a key family member, using the NIMH Family Interview for Genetic Studies, FIGS. 43 Consensus diagnostic evaluation was carried out by two senior clinicians reviewing independently all diagnostic information and assigning ICD-10 Diagnostic Criteria for Research (DCR) 44 and DSM-IV 45 lifetime diagnoses, being blinded to family relatedness and test scores of the subjects. All diagnostic disagreements were resolved through a joint case review.
Neurocognitive assessment protocol Probands, relatives and controls completed a neurocognitive battery assessing seven domains of function. General intelligence: The National Adult Reading Test, NART 46 provided an estimate of premorbid WAIS-R IQ; the Shipley Institute of Living Scale 47 was used to estimate current intellectual functioning, converted to WAIS-R IQ. Sustained attention: Two high-processing load versions of the Continuous Performance Task (CPT) were used: the degraded stimulus version, CPT-DS, 48 and the identical pairs version, CPT-IP. 49 Whereas CPT-DS involves an increased demand on visual encoding, CPT-IP selectively challenges working memory. Hit rate, reaction time for hits, error of commission rate (false alarms), and overall measures of signal detection, dL, and bias, cL 50 were derived for both tasks. 57 
GoM analysis
The neurocognitive and personality trait data were analysed using the GoM methodology which integrates multiple measurements into a limited number of composite graded traits. GoM, a mathematical typology developed for studies of complex biological systems, 40, 41 is one of the family of latent structure analysis methods 58 and is based on the concept of fuzzy sets. It resolves heterogeneity across multiple attributes (eg symptoms, psychological test measurements, or any other biological variable) by assigning each individual to several analytically derived latent classification categories or pure types (PTs) and quantifies the degree to which an individual belongs to any given PT. PTs are described by profiles of attributes where the probability (l kj ) of each attribute is estimated, being manifested by an individual belonging entirely to one PT. PT coefficients (l kj ) and scores (g ik ) on individual membership in the PTs are estimated simultaneously from the data matrix by maximum likelihood. The g ik scores of an individual on all PTs are constrained to be non-negative and sum up to 1.0, thus enabling a quantification of an individual's membership in more than one PT. GoM has been used to analyse large data sets from the WHO International Pilot Study of Schizophrenia 59 and a historical cohort of E Kraepelin's dementia praecox cases; 60 it has also been used in genetic research into Alzheimer's disease; 61 and in a replication of mapping the IDDM11 locus in diabetes. 62 Using GoM and 68 input variables, we obtained an optimal partitioning of the data set into five PTs. As a concurrent validator, we performed latent class analysis of the same data set, which also resulted in five classes with a 60% overlap (P ¼ 0.000) in the clustering of the variables by the two methods.
Each PT identifies a particular 'idealised' multivariate configuration of neurocognitive and personality traits, approximated by the 'real' individuals in the sample to varying degrees, specified by their GoM scores (g ik ) on each one of the PTs. Assignment of principal membership to one of the PTs is based on the observed greatest deviation of each individual's scores from the mean g ik for each PT. Thus, the study population was distributed into five clusters, with individuals within each cluster approximating the latent structure of one of the PTs.
PT I: Represented by probands with schizophrenia and a small number of affected siblings; characterised by both low premorbid and low current IQ; high rate of irrelevant intrusions on delayed word recall; abnormal performance on both sustained attention tasks, with a particularly marked deficit on the degraded stimulus task (CPT-DS), suggesting a predominantly frontoparietal impairment. This PT also exhibits more nonright handedness and soft neurological signs than any other GoM type. It is further characterised by high scores on 'positive' schizotypy (SPQ odd beliefs, magical ideation) and on TCI novelty seeking.
PT II: Includes probands as well as unaffected siblings and parents. Both premorbid and current IQ are low, but in contrast to PT I, there is a significant postonset drop in IQ from the premorbid to the current level. Compared to PT I, this type is more impaired on verbal fluency and on CPT-IP, the attention task challenging working memory, and less impaired on the degraded stimulus task CPT-DS, which assesses attentional control of visual encoding. It exhibits a high score on 'negative' schizotypy (SPQ constricted affect) and lower scores than PT I on odd beliefs and magical ideation.
PT III: The profile is normative, in the sense that performance across all tasks is within 71SD of the control means. It includes mainly unaffected relatives and controls, as well as a minority of schizophrenia patients with apparently less impaired neurocognitive performance.
PT IV: Expressed in unaffected relatives and controls, includes a small number of probands. It differs from PT III by a lower premorbid IQ and a higher rate of nonright handedness.
PT V: Consists mainly of parents, controls, and a small number of probands with schizophrenia over age 55. It is characterised by a relatively high premorbid IQ and an age-related decline of general ability.
With the exception of a low positive correlation (r ¼ 0.13) between PT I and PT II, the PTs were uncorrelated. Within each cluster of subjects assigned to the same PTs, the neurocognitive profiles were qualitatively similar for clinically affected and unaffected individuals. However, as shown in PT II (Figure 1 ), schizophrenia patients display more conspicuous deviations than their unaffected relatives on measures of general ability, sustained attention and verbal memory.
Clinical correlates of GoM PTs
We selected a priori 17 SCAN symptom clusters indexing positive symptoms, negative symptoms, affective symptoms, and disorganisation. Comparison of the symptom profiles indicated that whereas both PT I and PT II cases scored high on delusions and auditory hallucinations, PT I subjects had higher scores on elation, Schneiderian first-rank symptoms, intensity of delusions, bizarre delusions and positive thought disorder. PT II subjects, on the other hand, had higher scores on negative thought disorder (poverty of content of speech, restricted quantity of speech, nonsocial speech) and flat or incongruous affect (blunting, incongruity, reduced facial and voice expression). The comparison of the research diagnoses of ICD-10 clinical subtypes of schizophrenia and related disorders revealed a significant difference (P ¼ 0.015) in the ratios of paranoid to nonparanoid schizophrenia within PT I and PT II. While paranoid schizophrenia was the modal (39.5%) diagnosis of subjects assigned to PT II, it accounted for only 28.9% of the diagnoses in PT I (the odds ratio for a subject with a diagnosis of paranoid schizophrenia to be PT II, rather than PT I, was 5.35; CI 1.50-19.11). In contrast, nonparanoid subtypes were over-represented (55.3%) in PT I. Notably, all cases diagnosed with rare or atypical forms of schizophrenia (catatonic, hebephrenic, simple, 'other' and 'unspecified') turned out to have the PT I neurocognitive phenotype. Furthermore, PT I patients had a greater mean number 
Familial aggregation of GoM PTs
Using ANOVA, we found a highly significant (Po0.000) familial aggregation of GoM scores for PT II, significant for PT III (Po0.04) and PT IV (Po0.03), but no significant familial aggregation for PT I and PT V ( Table 1 ). The additive genetic heritability (using maximum likelihood variance decomposition as implemented in SOLAR 63 ) was 0.42 for PT II and 0.35 for the combined PT I and PT II phenotype (Table 1) . A plausible interpretation of these data is that PT I and PT II, which select the majority of probands with schizophrenia, represent multivariate phenotypes differing in the strength of their association with the genetic liability to schizophrenia.
Cell lines and genomic DNA Permanent cell lines were established from all probands by transforming lymphocytes with EpsteinBarr virus using standard techniques. 64 Genomic DNA was prepared from whole blood or cell lines using the salting out method. 65 Polymerase chain reaction (PCR) assays were performed in 8 ml volume reactions containing 10 ng genomic DNA; 2.5 mM of each dNTP; 0.2-0.6 mM of each primer pair labelled with Fam, Hex, or Tet; 0.8 ml of 10 Â buffer (Perkin-Elmer, Norwalk, CT, USA); 1.5-2.5 mM MgCl 2 ; and 0.2 units AmpliTaq Gold Polymerase (Perkin Elmer). PCR assays were performed in an Applied Biosystems (Foster City, CA, USA) 9600 Thermocycler by denaturing for 10 min at 941C, then 15 cycles of 30 s at 941C, 15 s at 601C, and 15 s at 721C. Another 20 cycles of 30 s at 941C, 15 s at 651C, and 15 s at 721C were performed, followed by a final extension step of 10 min at 721C. Fluorescently labelled markers were analysed on Applied Biosystems 373 or 310 Genetic Analysers, and the data were further analysed using Applied Biosystems GeneScan and Genotyper software. Polymorphic bands were scored and alleles were assigned to the pedigree members.
Markers typed Chromosome 6: D6S263; D6S429; D6S285; D6S1029; D6S276; D6S1014; D6S439; D6S497; D6S1019; D6S426; D6S257; D6S445; D6S1613; D6S424; D6S283; D6S301; D6S268; D6S474; D6S267.
Chromosome 10: D10S191; D10S1423; D10S197; D10S1426; D10S604.
Chromosome 22: D22S420; D22S539; D22S315; D22S280; D22S278; D22S283; D22S423; D22S274; D22S1169.
Linkage analyses
Parametric and nonparametric multipoint analyses were carried out using GENEHUNTER. 66 Quantitative trait analyses were performed with the SOLAR program. 63 Allele frequencies for all calculations were derived from unrelated individuals.
We used a combination of clinical diagnosis and GoM scores (g ik ) to stratify the entire sample (ie, both clinically affected and clinically unaffected individuals) into 10 liability classes (Table 2 ). For parametric linkage analyses, all individuals with a diagnosis of schizophrenia or schizophrenia spectrum disorder were assigned to liability class I. Liability class assignment for all remaining, clinically unaffected subjects was determined by their GoM scores (g ik ) on the PT II composite neurocognitive phenotype which displayed the highest degree of familial aggregation. As the lack of significant heritability for PT I does not preclude influence of genetic factors on its expression, combined PT I and PT II scores were used to stratify the sample in an alternative analysis.
Two genetic models were calculated: a low-penetrance model with a maximum penetrance of 0.2, and a high-penetrance model with a maximum penetrance of 0.9. Disease frequency was set at 0.1 and 0.02, respectively. Separate analyses were carried out with those single components of the composite phenotype which made the greatest contribution to the maximum likelihood function differentiating the GoM PTs: general ability (premorbid IQ, current IQ); sustained attention (CPT-IP); and delayed word recall (RAVLT).
Results
A total of 61 families (comprising 259 individuals) with at least one proband diagnosed with schizophrenia or schizophrenia spectrum disorder were potentially available for linkage analyses (we did not extend the families beyond first-degree relatives). Among the family members, 12 were deceased; 14 refused to participate in the study; and another five 
Variance component linkage analysis
We first performed two-point linkage analysis using the variance component procedure implemented in SOLAR. None of the markers typed on chromosome 10 or 22 showed any lod scores above 0.7. A maximum two-point lod score of 2.65 was obtained on chromosome 6 with marker D6S276 for the combined PT I and PT II phenotype. Six more markers on chromosome 6 resulted in lod scores above 1.0 (D6S1014, D6S1613, D6S429, D6S257, D6S426, D6S1019). The maximum lod score for PT II (1.43) was obtained with the same marker D6S276 (Table 3) . In a second step, we carried out multipoint variance component linkage analysis at constant increments of 1 cM (Figure 1 ). The maximum lod score observed for combined PT I and PT II was 2.51 at 44 cM. For PT II, the maximum lod score was 1.59 at 56 cM. As with the two-point analyses, none of the lod scores were above 0.6 on chromosomes 10 and 22 ( Figure 2) .
Variance component linkage analysis between the same markers and single neurocognitive measures used as correlated phenotypes (CPT-IP, current IQ, premorbid NART IQ, and RAVLT total word recall) resulted in only weakly positive lod scores (Table 4) .
Parametric linkage analysis
Results from the parametric linkage analysis are shown in Figure 3 . Two peaks about 4 cM apart were observed for both PT II and the combined PT I/PT II phenotype. The highest peak with a maximum lod score of 2.11 was calculated at D6S439 for the combined phenotype using the low-penetrance model. However, the peak for the high-penetrance model was only marginally lower (2.02) as were the peaks for the PT II phenotype (MLS 2.01 for the low-penetrance model and 1.98 for the high-penetrance model). A second, lower peak was calculated close to the marker D6S276.
In order to test for genetic differences between the two phenotypes (PT I and PT II) we subdivided the families on the basis of the ratio of the GoM scores (g ik ) PT I/PT II, for each proband. PT I probands were defined by a PT I/ PT II ratio of greater than 1.5 and PT II probands by a PT I/ PT II ratio of less than 1.5. For families with a PT II proband, we obtained maximum lod scores above 2.6 at D6S276 and D6S439 (Figure 4) . Lod scores for PT I families at the same locations were negative (À1.16 and À0.68, respectively). The highest positive lod score for the PT I subgroup was only slightly above 1 between the markers D6S474 and D6S276, 70 cM away from the peak of the families with PT II probands. In a final analysis, we increased penetrance values for liability class 1 to 0.9, setting the other liability class values accordingly (see Table 2 ). The frequency of the disease allele was assumed to be only 0.02. Under this model, the maximum lod scores were above 3 for the PT II subgroup of families. Linkage was calculated for two different genetic models, one with a maximum penetrance value of 0.2 (low-penetrance model) and a gene frequency for the disease allele 0.1, and the other with a maximum penetrance of 0.9 and a gene frequency for the disease allele 0.02. All individuals with a diagnosis of a schizophrenia or schizophrenia spectrum disorder were assigned to liability class I. For all other family members, PT II or PT I and PT II combined g ik scores were used for liability class assignment.
Discussion
Despite the high heritability of schizophrenia, identifying susceptibility genes contributing to its aetiology has proven to be a daunting task. 67 Schizophrenia is a complex disorder 68 characterised by a widely varied clinical phenotype, low penetrance and existence of phenocopies. The genetic model currently commanding broad agreement is one of multiple genes of small-to-moderate effect increasing the risk of Distance in cM Lod score Figure 4 Results from parametric multipoint linkage analysis for chromosome 6p. Individuals with a diagnosis of schizophrenia or a schizophrenia spectrum disorder were considered affected. Unaffected relatives contributed information to linkage analyses based on their PT II scores. Families were subdivided based on the ratio of PT I to PT II scores. Open circles: multipoint lod scores for the low-penetrance model and families with a PT I/PT II score ratio greater than 1.5. Solid squares: low-penetrance model and families with a PT I/PT II score ratio less than 1.5. Open triangles: high-penetrance model and families with a PT I/PT II score ratio less than 1.5.
schizophrenia through epistatic gene-gene interactions, as well as interactions with nongenetic risk factors. 69 Under this model, the power to detect susceptibility genes depends strongly on the magnitude of the effect of the individual gene under investigation. 70 For an oligogenic disorder, the sample size required is very large 71 and the difficulty in recruiting a sufficient number of families is a major constraint. 8 In the case of schizophrenia, the majority of probands do not have a first-degree relative affected with the same disorder, and therefore only a minority of potential families are informative for linkage analysis. 72, 73 Thus, studies based exclusively on diagnosis are unlikely to generate adequate power to detect susceptibility genes.
In the present study, we applied a novel approach, capable of overcoming some of the limitations of clinical diagnosis as phenotype, by identifying composite quantitative traits indexing neurocognitive deficits known to occur both in patients with schizophrenia and in a proportion of their unaffected first-degree relatives. We used a mathematical typology based on fuzzy statistical models, 40, 41 which identifies latent patterns, or PTs, among multiple variables and allows individuals to be partly assigned to more than one such PT by computing GoM scores for each subject on all of the PTs. Using as input variables 68 neurocognitive and personality test measures, but no symptoms or clinical history items, we applied a maximum likelihood criterion to obtain an optimal partitioning of the data matrix into five PTs, each identifying a unique profile of neurocognitive and personality traits. Two of the PTs (PT I and PT II) were confined to probands with schizophrenia and their first-degree relatives, whereas PTs III-V were mainly represented by unaffected relatives and controls. PT I and PT II were associated with independently assessed, distinct clinical profiles of lifetime symptoms and severity of illness. Whereas PT II, and to a lesser degree PTs III and IV, aggregated significantly in families, PTs I and V did not. However, the combination PT I and PT II did show significant familiality. As it accounted for 74% of the schizophrenia patients in the sample, we assumed that the conflation of these two PTs represents a correlated phenotype that reflects genetic vulnerability to schizophrenia.
Compared to conventional linkage analysis, the correlated phenotype approach, as applied here, offers three advantages. Firstly, it allows inclusion of families ascertained through a proband with schizophrenia, irrespective of the presence or absence of other clinically affected family members. Secondly, as PT coefficients (g kj ) treat susceptibility to neurocognitive dysfunction as a quantitative trait (instead of a dichotomy of affected and unaffected status), all individuals in the study sample are potentially informative. Thirdly, by comparing the analysis of a dichotomised trait with that of a quantitative version of the same trait, it can be shown that both precision and power to detect linkage increase when the trait is coded as a continuous variable. 74, 75 If a composite trait is constructed, integrating a correlated structure of multiple traits, power can be further increased. 76, 77 Based on published results, 9, 14, [78] [79] [80] [81] [82] [83] we selected markers on chromosomes 6, 10 and 22, and tested them for linkage. Variance component linkage analysis revealed maximum positive lod scores above 2.5 for both two-point and multipoint analysis with markers on chromosome 6 for the combined PT I and PT II phenotype (lod scores for PT II alone were also positive but overall lower). The peak lod scores for the combined PT I and PT II phenotype were calculated with marker D6S276, located at the telomeric end of the HLA region.
In a second set of calculations, we included the ICD-10/DSM-IV diagnosis of schizophrenia in the definition of the affection status but retained in the analysis all 'unaffected' individuals by stratifying them into liability classes on the basis of their PT II or PT I and PT II g ik scores. Using this approach enabled an increase in the power to detect linkage since not only affected but also a large proportion of the clinically unaffected individuals became informative. Power calculations based on the 61 families using the SLINK program demonstrated a nearly six-fold increase in the average lod score for a linked marker to a putative disease locus (Table 5) .
This approach is not restricted to families with more than one family member affected with schizophrenia and therefore allows aggregating much larger data sets. As with variance component analysis, the highest positive lod scores were calculated with markers from chromosome 6. The peak lod scores of about 2 were closer to the centromeric end of the HLA region at D6S439.
The low heritability of PT I, together with the finding of mixed handedness and soft neurological signs, argues in favour of a nongenetic contribution to the aetiology of the schizophrenic syndrome in this subset of families. We therefore subdivided the families on the basis of the probands' PT I and PT II g ik scores. As the g ik scores of an individual on all PTs are constrained to be non-negative and sum up to 1.0, they enable a quantification of an individual's membership in more than one PT. We considered a family to be PT I if the PT I score of the proband was at least 1.5 times the PT II score. A total of 21 families (34.4% of all families) with a proband having a ratio of PT I to PT II scores !1.5 were identified and analyses were conducted for both groups of families separately (Figure 4) . Multipoint lod scores for the two groups were strikingly different. Lod scores for PT I families were negative for markers that resulted in positive results in PT II families and positive for markers that resulted in negative lod scores in PT II families. For the PT II sample, lod scores above 2.0 were calculated, stretching over a 14 cM area including the entire HLA region. Lod scores greater than 2.6 in the low-penetrance model increased to above 3.0 in the high-penetrance model.
One possible explanation of the results is that PT II may be constrained by a different genetic profile than PT I, suggesting that different components of the schizophrenia phenotype are influenced by different genetic loci. As it is unlikely that any of the genes involved code directly for schizophrenic signs and symptoms, such as delusions, hallucinations or thought disorder, we assume that the putative genes influence their occurrence indirectly via combinations and interactions of basic processes at synaptic and neural circuitry level, phenotypically expressed as neurocognitive deficits and personality traits. Notably, variance component linkage analysis of single neurocognitive measures, such as the CPT-IP, which contribute to the differentiation of PT I and PT II, did not show any lod scores greater than 0.7, and positive lod scores above 2.0 were restricted to the multivariate phenotype. Therefore, the genetic effects are more likely to involve multiple intermediate and interactive steps, thus resulting in a very complex relationship between genes and phenotype. We suggest that the multivariate PT II neurocognitive phenotype can be viewed as a pleiotropic manifestation of genes underlying the susceptibility to a clinical form of schizophrenia characterised primarily by paranoid delusions and negative symptoms.
The results presented provide suggestive evidence 84 of linkage for susceptibility gene(s) for schizophrenia located on the short arm of chromosome 6. Several other groups have reported positive linkage findings on chromosome 6p, 4, 6, 12, 14, 78, 80, 81, [85] [86] [87] and it has been argued that the 6p findings reach the threshold 84 for significant linkage. However, the locations of the markers showing the strongest evidence for linkage vary substantially across the studies. In this present study, maximum positive lod scores were calculated with markers close to or within the HLA region. One possibility is that HLA antigens themselves confer susceptibility to schizophrenia. 88 Alternatively, this effect may be caused by another gene in close proximity. 89 The HLA region is extremely gene rich (the HLA class III region alone contains at least 59 genes and is the highest gene density region. 90 Positive associations have been reported between schizophrenia and polymorphisms in the NOTCH4 gene. 91 However, replication attempts have been largely negative. [92] [93] [94] [95] [96] A potential role of the tumour necrosis factor alpha (TNFa) gene for susceptibility to schizophrenia has been proposed by Bouin et al, 97 who reported a positive association between a biallelic base exchange polymorphism that directly affects TNFa plasma levels and schizophrenia. TNFa, produced by glial cells, influences synaptic plasticity and modulates responses to neural injury. 98 More recently, a significant association in the region 6p24-21 has been reported for the dysbindin gene. 99 Considering the complex inheritance and likely genetic heterogeneity of schizophrenia, it may be extremely difficult, if not impossible, to demonstrate an aetiological role for any of these genes. However, by identifying susceptible individuals based on indicators that are more proximal to the genetic liability, it may be possible to obtain more coherent genetic findings. The results reported here indicate that neurocognitive and personality measures in schizophrenia patients and their biological relatives aggregate nonrandomly into distinct patterns or PTs. Two of the pure types (PT I and PT II) select the majority of clinically affected subjects and thus index a high risk for schizophrenia. Of these, PT II is familial and heritable, whereas PT I suggests a greater influence of environmental factors in its aetiology. The distinction between these two types in the genetic analysis of schizophrenia may be a step towards identifying more homogeneous samples for both linkage and association studies. a Affected subjects with schizophrenia or schizophrenia spectrum disorders only. b Affected subjects with schizophrenia or schizophrenia spectrum disorders, plus unaffected relatives, liability stratified by GoM scores (g ik ) for PT II. c Affected subjects with schizophrenia or schizophrenia spectrum disorders, plus unaffected relatives, liability stratified by GoM scores (g ik ) for PTs I and II combined. Genetic models and liability classes assigned as described in Table 2 and text. Results are based on 1000 simulations using SLINK (Ott, 1989; Weeks et al, 1990), assuming a marker with heterozygosity of 0.7 located 5 cM distant to a putative disease locus.
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